Lexicon Pharmaceuticals (NASDAQ: LXRX), a biopharmaceutical company leveraging its proprietary Genome5000™ program to develop therapeutics for the treatment of disease such as diabetes, metabolism, oncology and neuropathic pain, announced that the Food and Drug Administration (FDA) has reiterated its rejection of the Company’s New Drug...
Enlivex Therapeutics (NASDAQ: ENLV), a Company focused on developing allogenic therapies for immune system rebalancing, announced positive interim efficacy data from its ongoing Phase Ib clinical trial in patients with severe sepsis. The analysis in based on data collated from 43 patients with severe sepsis,...
Human Immunodeficiency Virus (HIV) compromises the body’s immunity by attacking CD4 cells (a type of T cell), exposing it to a host of infections and diseases and ultimately leading to the development of AIDS. According to data provided by Centres for Disease Control and Prevention,...
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes the body’s immune system to attack healthy tissue causing inflammation, photosensitivity, oral ulcers, pleuritis, joint pain, arthritis, fever and a butterfly rash. In the long-run it can affect the kidneys, brain and heart as well....
The stocks of Cortexyme, Inc (NASDAQ: CRTX), a clinical stage biopharmaceutical company engaged in developing novel therapeutics for Alzheimer’ disease, surged by almost 70% on its debut on the stock market on May 9. Its market value jumped to $750 million by end of trading...
The Muscular Dystrophy Association describes Duchenne Muscular Dystrophy (DMD) as a fatal, X-linked genetic neuromuscular disorder that leads to progressive, irreversible loss of muscle function, including the heart and lungs. It has an X-linked recessive inheritance pattern and is acquired by a “Carrier” mother. Globally, 1 in...
Anticoagulants have wide applications for prevention of blood clots in treatment of conditions such as pulmonary embolism, deep vein thrombosis (DVT), atrial fibrillation, stroke management and thromboembolic disorders. According to estimates available on CDC, approximately 900,000 people are affected by DVT/PE each year in the...
Metastatic brain tumor, also known as secondary cancer, is the most common brain tumor in adults and is estimated to affect between 200,000 and 300,000 people per year, according to The American Brain Tumor Association. The growth in the metastatic cancers market is owing to improved diagnostics, increasing...
